Aflibercept

1 Drug classified under this active ingredient

Ocular Antineovascularisation Agent. Aflibercept 40 mg/ml.
VIAL (Sol. for Intravitreal inj.): 40 mg/ml.
Wet AMD: Initiat. tmt. 1 inj. per month
for 3 consec. doses, follow.by 1 inj.
every 2 mths. After the 1st 12 mths. of
tmt. may exten. tmt. interv. based on
vis. and anatom. outcomes. Monitor.
Sched. should be determin. by physic.
Macu. Oedem. due to CRVO: Initiat.
tmt. 1 inj. per month, follow. by 1 inj.
monthly. Diabetic Macular Oedema:
Initiat. tmt. 1 inj. per month for 5
consec. doses, follow. by 1 inj. every 2
mths. After the 1st 12 mths. of tmt. may
exten. tmt. interv. based on vis. and
anatom. outcomes.
Tmt. of neovasc. (wet) AMD. Tmt. of visual
impair. due to macular edem. second. to
branch RVO or central RVO. Tmt. of visual
impair. due to DME in adult.
C/I: Hypersens.; Act. or suspect. ocular or
perioc. infec.; Act. severe intraoc. inflam.